Elevate your enterprise data technology and strategy at Transform 2021.
Juvaris BioTherapeutics, a Pleasanton, Calif. company developing vaccine products for influenza and pneumonia, said it has raised the first $6 million half of its first round of funding .
The financing comes from Kleiner Perkins, the well-known venture firm that has focused its investments in the pandemic area with its “Pandemic & Biodefense Fund.”
Juvaris said it will close the second part of its round in 120 days, and that the total raised will be $12 million.
The company is also pursuing immunotherapy products for Hepatitis B and Biodefense applications.
The funds permit the company to buy assets from Valentis.
The company’s statement is here.
(Story first published 1/9)
VentureBeatVentureBeat's mission is to be a digital town square for technical decision-makers to gain knowledge about transformative technology and transact. Our site delivers essential information on data technologies and strategies to guide you as you lead your organizations. We invite you to become a member of our community, to access:
- up-to-date information on the subjects of interest to you
- our newsletters
- gated thought-leader content and discounted access to our prized events, such as Transform 2021: Learn More
- networking features, and more